Literature DB >> 10976694

Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas.

R D Odze1, C A Brown, C J Hartmann, A E Noffsinger, F Fogt.   

Abstract

Recent molecular studies have shown that there are differences in the prevalence and timing of certain molecular events between chronic ulcerative colitis (CUC)-associated dysplastic lesions and non-CUC-related sporadic adenomas. However, little is known regarding the molecular features of a specific subtype of CUC-related dysplasia-associated lesion or mass (DALM) that clinically, endoscopically, and pathologically resemble sporadic adenomas, and whether these lesions can be separated from non-CUC-related sporadic adenomas on the basis of their molecular genotype. Therefore, the purpose of this study was to evaluate loss of heterozygosity (LOH) of 3p, APC, and p16 in a specific group of CUC-associated "adenoma-like" DALMs and to compare the results of this tumor with those in a well-defined group of CUC-associated non-adenoma-like DALMs and non-CUC-associated sporadic adenomas. Polypectomy or resection specimens from 21 CUC patients with an adenoma-like DALM, 8 CUC patients with at least one nonadenoma-like DALM (12 lesions in total), and 23 non-CUC patients with a sporadic adenoma were evaluated for LOH of 3p, APC, and p16 by PCR analysis. The results were compared among the three different study groups and correlated with the clinical features of the patients and the pathology of their tumors. Chronic ulcerative colitis-associated adenoma-like DALMs showed LOH of 3p in five of 18 (28%) cases. This value was not significantly different from the 5% of non-CUC sporadic adenomas (p = 0.14) that were positive. However, 50% of CUC-associated non-adenoma-like DALMs were positive for LOH of 3p, and this value was significantly higher (p = 0.01) than the other groups. The frequency of LOH of APC did not differ significantly between the three patient groups (33%, 33%, and 43% in the three groups, respectively). Similar to the 3p results, CUC-associated adenoma-like DALMs and non-CUC-associated sporadic adenomas showed a similar low frequency of positivity for LOH of p16 (5% and 4%, respectively) in comparison to 56% of CUC-associated non-adenoma-like DALMs (p = 0.003). For all markers, no significant differences were detected in the CUC-associated adenoma-like DALM group between lesions that occurred within colitis compared with those that occurred in areas not involved by colitis. Chronic ulcerative colitis-associated non-adenoma-like DALMs have a different molecular genotype than CUC-related adenoma-like DALMs and non-CUC sporadic adenomas. Our data also suggests that the latter two groups of neoplasms may in fact represent a similar, if not identical, pathogenetic entity.

Entities:  

Mesh:

Year:  2000        PMID: 10976694     DOI: 10.1097/00000478-200009000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

Review 1.  Cancer risk in IBD: how to diagnose and how to manage DALM and ALM.

Authors:  Helmut Neumann; Michael Vieth; Cord Langner; Markus F Neurath; Jonas Mudter
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 2.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

Review 3.  [Polypoid dysplasia in inflammatory bowel disease: differential diagnosis and further diagnostic and therapeutic approaches].

Authors:  S Warich-Eitel; T Katzenberger; M Eck
Journal:  Pathologe       Date:  2011-07       Impact factor: 1.011

4.  Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view.

Authors:  John B Kisiel; David A Ahlquist
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

5.  Colitic Cancer Develops Through Mutational Alteration Distinct from that in Sporadic Colorectal Cancer: A Comparative Analysis of Mutational Rates at Each Step.

Authors:  Toshiaki Tanaka; Takashi Kobunai; Yoko Yamamoto; Shigenobu Emoto; Koji Murono; Manabu Kaneko; Kazuhito Sasaki; Kensuke Otani; Takeshi Nishikawa; Kazushige Kawai; Keisuke Hata; Hiroaki Nozawa; Toshiaki Watanabe
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

Review 6.  Endoscopic and pathological aspects of colitis-associated dysplasia.

Authors:  Fiona D M van Schaik; G Johan A Offerhaus; Marguerite E I Schipper; Peter D Siersema; Frank P Vleggaar; Bas Oldenburg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09-22       Impact factor: 46.802

Review 7.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.

Authors:  J B Kisiel; T C Yab; F T Nazer Hussain; W R Taylor; M M Garrity-Park; W J Sandborn; E V Loftus; B G Wolff; T C Smyrk; S H Itzkowitz; D T Rubin; H Zou; D W Mahoney; D A Ahlquist
Journal:  Aliment Pharmacol Ther       Date:  2013-01-24       Impact factor: 8.171

Review 9.  Techniques for targeting screening in ulcerative colitis.

Authors:  David Paul Hurlstone; Steve Brown
Journal:  Postgrad Med J       Date:  2007-07       Impact factor: 2.401

Review 10.  Microscopic features of colorectal neoplasia in inflammatory bowel diseases.

Authors:  Aude Bressenot; Virginie Cahn; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.